Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 10/20 | 0.52 |
| ▸ | ACACA | Q13085 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17050832 | 0.87 | ACACB (0.57) | ACACBACACACYP3A4CYP2C9MAPK1 | |
| SCHEMBL17050453 | 0.84 | ACACB (0.53) | ACACBACACACYP3A4CYP2C9MAPK1 | |
| SCHEMBL17050833 | 0.82 | ACACB (0.46) | ACACBACACACYP3A4CYP2C9MAPK1 | |
| SCHEMBL17050837 | 0.80 | ACACB (0.62) | ACACBACACACYP3A4CYP2C9MAPK1 | |
| SCHEMBL8025062 | 0.78 | HAO1 (0.48) | KMT2ASMN1; SMN2KDM4EPOLB | |
| SCHEMBL17050518 | 0.74 | ACACB (0.70) | ACACBACACACYP3A4CYP2C9MAPT | |
| SCHEMBL9503543 | 0.74 | MAPT (0.49) | ACACBMAPTCSNK2A1GLASMN1; SMN2 | |
| SCHEMBL8026494 | 0.73 | L3MBTL1 (0.44) | KMT2AKDM4EL3MBTL1 | |
| SCHEMBL17050840 | 0.72 | ACACB (0.68) | ACACBACACACYP3A4CYP2C9MAPT | |
| SCHEMBL17050834 | 0.72 | ACACB (0.71) | ACACBACACACYP3A4CYP2C9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | ACSS2, ACACB, ACAT2 | ACACB 2/4885ACACA 10/4885CYP3A4 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.